BrainStorm Cell Therapeutics Enters Securities Purchase Agreement

Tip Ranks
2025.11.14 22:32
portai
I'm PortAI, I can summarize articles.

BrainStorm Cell Therapeutics entered a securities purchase agreement with Labrys Fund II, L.P., issuing a $143,750 promissory note and receiving $121,500 after fees. The note is convertible into shares upon default. BrainStorm also announced a decrease in net loss for Q3 2025 and updates on its NurOwn Phase 3b ALS trial. Analysts rate BCLI stock as Hold with a $6.60 price target, but TipRanks' AI Analyst rates it as Underperform due to financial challenges and skepticism about NurOwn's efficacy.

Meet Your ETF AI Analyst

  • Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
  • Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.

The latest announcement is out from Brainstorm Cell Therapeutics ( (BCLI) ).

On November 10, 2025, BrainStorm Cell Therapeutics entered into a securities purchase agreement with Labrys Fund II, L.P., issuing a promissory note of $143,750 and receiving $121,500 after fees. The note is convertible into shares upon default, with specific payment terms leading to maturity on November 10, 2026. Additionally, BrainStorm announced its third-quarter financial results for 2025, highlighting a decrease in net loss compared to the previous year, and provided updates on its NurOwn Phase 3b clinical trial for ALS, which has received FDA clearance. The trial aims to enroll 200 participants and is designed to support a Biologics License Application. A Citizen Petition was filed with the FDA by the ALS community, underscoring interest in NurOwn’s potential.

The most recent analyst rating on (BCLI) stock is a Hold with a $6.60 price target. To see the full list of analyst forecasts on Brainstorm Cell Therapeutics stock, see the BCLI Stock Forecast page.

Spark’s Take on BCLI Stock

According to Spark, TipRanks’ AI Analyst, BCLI is a Underperform.

Brainstorm Cell Therapeutics’ stock score is significantly impacted by its financial performance challenges, including ongoing losses and negative cash flows. While there are strategic advancements and partnerships aimed at derisking the regulatory pathway, the company’s valuation and technical indicators reflect a bearish outlook. Investors should be cautious due to financial constraints and skepticism regarding the efficacy of its lead treatment, NurOwn.

To see Spark’s full report on BCLI stock, click here.

More about Brainstorm Cell Therapeutics

BrainStorm Cell Therapeutics Inc. is a leading developer of autologous adult stem cell therapies for neurodegenerative diseases. The company’s proprietary NurOwn platform uses autologous mesenchymal stem cells to produce neurotrophic factor-secreting cells, designed to modulate neuroinflammation and promote neuroprotection. NurOwn is BrainStorm’s lead investigational therapy for amyotrophic lateral sclerosis (ALS) and has received Orphan Drug designation from both the U.S. FDA and the European Medicines Agency.

Average Trading Volume: 21,150

Technical Sentiment Signal: Sell

Current Market Cap: $6.64M

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer